OTC Beconase Hayfever Nasal Spray Would Have Strong Safety Profile – GSK
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline Consumer Healthcare's Beconase Hayfever nasal spray has an appropriate safety profile for OTC use, the firm says in a Sept. 9 "consultation letter" filed with the UK Medicines Control Agency
You may also be interested in...
Glaxo’s Garnier Rebuts Schering Prediction On Flonase Switch
GlaxoSmithKline CEO Jean-Pierre Garnier called premature a prediction by Schering-Plough CEO Fred Hassan that FDA could approve a nasal-inhaled steroid for over-the-counter use this year
Glaxo’s Garnier Rebuts Schering Prediction On Flonase Switch
GlaxoSmithKline CEO Jean-Pierre Garnier called premature a prediction by Schering-Plough CEO Fred Hassan that FDA could approve a nasal-inhaled steroid for over-the-counter use this year
Glaxo’s Garnier Rebuts Schering Prediction On Flonase Switch
GlaxoSmithKline CEO Jean-Pierre Garnier called premature a prediction by Schering-Plough CEO Fred Hassan that FDA could approve a nasal-inhaled steroid for over-the-counter use this year